DelveInsight’s “Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Age-related Macular Degeneration, historical and forecasted epidemiology as well as the Age-related Macular Degeneration market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Age-related Macular Degeneration market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Age-related Macular Degeneration market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Age-related Macular Degeneration Market Insights
Age-related Macular Degeneration Overview
Age-related macular degeneration (AMD) is a leading cause of severe, irreversible blindness in developed countries worldwide, with a profound effect on the quality of life of affected individuals. With the increase in life expectancy bringing growth in the number of reported cases, it adds a significant burden on the health care systems with the expensive current standard of care.
Some of the key facts of the Age-related Macular Degeneration Market Report:
- The Age-related Macular Degeneration market size was valued at USD 9.840 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
- The total prevalent cases of Age-related Macular Degeneration were approximately 51,743,361 in the 7MM, which might increase at a decent CAGR by 2032
- The US accounted for approximately 17,282,569 prevalent cases of Age-related Macular Degeneration in the year 2021
- In EU-5 countries the highest number of prevalent cases of Age-related Macular Degeneration was observed in Germany with 7,850,793 cases in the year 2021, followed by France
- Key Age-related Macular Degeneration Companies: Alkeus Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Alexion., Evergreen Therapeutics, Ionis Pharmaceuticals, Roche, Luxa Biotechnology, Gemini Therapeutics, and others
- Key Age-related Macular Degeneration Therapies: ALK-001, Pegcetacoplan, Zimura, Danicopan, EG-301, ONIS-FB-LRx, RPESC-RPE4W, GEM103, and others
Get a Free sample for the Age-related Macular Degeneration Market Report-
https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market
Key benefits of the Age-related Macular Degeneration Market report:
- Age-related Macular Degeneration market report covers a descriptive overview and comprehensive insight of the Age-related Macular Degeneration Epidemiology and Age-related Macular Degeneration market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Age-related Macular Degeneration market report provides insights on the current and emerging therapies.
- Age-related Macular Degeneration market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Age-related Macular Degeneration market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Age-related Macular Degeneration market.
Download the report to understand which factors are driving Age-related Macular Degeneration epidemiology trends @ Age-related Macular Degeneration Epidemiological Insights
Age-related Macular Degeneration Market
The dynamics of the Age-related Macular Degeneration market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
Age-related Macular Degeneration Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Age-related Macular Degeneration Epidemiology Segmentation:
The Age-related Macular Degeneration market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Age-related Macular Degeneration
- Prevalent Cases of Age-related Macular Degeneration by severity
- Gender-specific Prevalence of Age-related Macular Degeneration
- Diagnosed Cases of Episodic and Chronic Age-related Macular Degeneration
Age-related Macular Degeneration Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Age-related Macular Degeneration market or expected to get launched during the study period. The analysis covers Age-related Macular Degeneration market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Age-related Macular Degeneration Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Discover more about therapies set to grab major Age-related Macular Degeneration market share @ Age-related Macular Degeneration market forecast
Age-related Macular Degeneration Therapies and Key Companies
- ALK-001: Alkeus Pharmaceuticals
- Pegcetacoplan: Apellis Pharmaceuticals
- Zimura: Iveric Bio
- Danicopan: Alexion.
- EG-301: Evergreen Therapeutics
- ONIS-FB-LRx: Ionis Pharmaceuticals/Roche
- RPESC-RPE4W: Luxa Biotechnology
- GEM103: Gemini Therapeutics
Age-related Macular Degeneration Market Drivers
- Increasing prevalence of wet Age-related Macular Degeneration
- Development in the field of gene therapy
- Robust pipeline
Scope of the Age-related Macular Degeneration Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Age-related Macular Degeneration Companies: Alkeus Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Alexion., Evergreen Therapeutics, Ionis Pharmaceuticals, Roche, Luxa Biotechnology, Gemini Therapeutics, and others
- Key Age-related Macular Degeneration Therapies: ALK-001, Pegcetacoplan, Zimura, Danicopan, EG-301, ONIS-FB-LRx, RPESC-RPE4W, GEM103, and others
- Age-related Macular Degeneration Therapeutic Assessment: Age-related Macular Degeneration current marketed and Age-related Macular Degeneration emerging therapies
- Age-related Macular Degeneration Market Dynamics: Age-related Macular Degeneration market drivers and Age-related Macular Degeneration market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Age-related Macular Degeneration Unmet Needs, KOL’s views, Analyst’s views, Age-related Macular Degeneration Market Access and Reimbursement
Age-related Macular Degeneration Market Barriers
- High cost of Age-related Macular Degeneration treatment
- Competitive treatment landscape
- Emerging biosimilar
Table of Contents
1. Age-related Macular Degeneration Market Report Introduction
2. Executive Summary for Age-related Macular Degeneration
3. SWOT analysis of Age-related Macular Degeneration
4. Age-related Macular Degeneration Patient Share (%) Overview at a Glance
5. Age-related Macular Degeneration Market Overview at a Glance
6. Age-related Macular Degeneration Disease Background and Overview
7. Age-related Macular Degeneration Epidemiology and Patient Population
8. Country-Specific Patient Population of Age-related Macular Degeneration
9. Age-related Macular Degeneration Current Treatment and Medical Practices
10. Age-related Macular Degeneration Unmet Needs
11. Age-related Macular Degeneration Emerging Therapies
12. Age-related Macular Degeneration Market Outlook
13. Country-Wise Age-related Macular Degeneration Market Analysis (2019–2032)
14. Age-related Macular Degeneration Market Access and Reimbursement of Therapies
15. Age-related Macular Degeneration Market Drivers
16. Age-related Macular Degeneration Market Barriers
17. Age-related Macular Degeneration Appendix
18. Age-related Macular Degeneration Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about Age-related Macular Degeneration treatment, visit @ Age-related Macular Degeneration Medications
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/